Glaxosmithkline
GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 71 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's reported carbon emissions
In 2023, GlaxoSmithKline (GSK) reported total Scope 1 and 2 emissions of approximately 102,000,000 kg CO2e in Great Britain. The company has set ambitious climate commitments, aiming to achieve net-zero greenhouse gas emissions across its value chain by 2045, using a 2020 base year. GSK has established near-term targets to reduce absolute Scope 1 and 2 emissions by 80% by 2030 and Scope 3 emissions by 80% within the same timeframe. Historically, GSK's emissions have shown significant figures, with Scope 1 emissions reaching about 633,000,000 kg CO2e and Scope 2 emissions at approximately 131,000,000 kg CO2e in 2021. The company is committed to reducing its Scope 1 and 2 emissions by 34% by 2025 from a 2017 baseline, alongside a 16% reduction in Scope 3 emissions by 2030 from the same base year. GSK's long-term strategy includes a 90% reduction in both Scope 1 and 2 emissions by 2045, as well as a similar target for Scope 3 emissions. These commitments align with the Science Based Targets initiative (SBTi) and reflect GSK's dedication to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
